Featured Publications
Oropharyngeal Carcinoma
Husain Z, Kang J, Lee N, Poon I. Oropharyngeal Carcinoma. Practical Guides In Radiation Oncology 2022, 15-25. DOI: 10.1007/978-3-030-99590-4_2.Peer-Reviewed Original ResearchLong-term treatment toxicityOropharyngeal squamous cell carcinomaCurative treatment optionSquamous cell carcinomaPatterns of failureElective coverageOropharyngeal carcinomaTreatment toxicityNeck malignanciesAccurate target delineationCell carcinomaDisease stageTreatment optionsCurative potentialPhysical examCommon headClinical scenariosRadiation oncologistsSurgical anatomyTarget volumeTarget delineationVolume coverageCarcinomaMultimodal imagingPrimary targetLarynx Cancer
Fan D, Kang J, Yu Y, Cahlon O, Riaz N, Lee N. Larynx Cancer. Practical Guides In Radiation Oncology 2022, 45-60. DOI: 10.1007/978-3-030-99590-4_4.Peer-Reviewed Original ResearchPostoperative radiotherapyLarynx cancerEarly stage squamous cell carcinomaOrgan preservation therapyEarly-stage diseaseLymph node metastasisAdvanced larynx cancerSquamous cell carcinomaStandard of careHigh-risk casesPre-treatment evaluationCommon clinical scenariosThin-cut CTPET/CTDefinitive chemoradiotherapyAdvanced diseaseLocoregional recurrencePreservation therapyGlottic larynxNode metastasisSubglottic extensionCell carcinomaLaryngeal cancerPhysical examOrgan preservation
2024
Outcomes of Reduced Elective Nodal Radiation Dose for Laryngeal, Hypopharyngeal and p16 Negative Oropharyngeal Cancers
Zakeri K, Shang T, Yu Y, Chen L, Shamseddine A, Kang J, Tsai C, Sherman E, Wong R, McBride S, Gelblum D, Riaz N, Lee N. Outcomes of Reduced Elective Nodal Radiation Dose for Laryngeal, Hypopharyngeal and p16 Negative Oropharyngeal Cancers. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e807. DOI: 10.1016/j.ijrobp.2024.07.1772.Peer-Reviewed Original ResearchP16-negative oropharyngeal squamous cell carcinomaNegative oropharyngeal squamous cell carcinomasOropharyngeal squamous cell carcinomaDistant recurrenceSquamous cell carcinomaNodal recurrenceRadiotherapy doseLocoregional recurrenceP16 statusCell carcinomaHypopharynx cancerP16-negative oropharyngeal cancerHead and neck cancer patientsRadiation doseElective nodal volumesP16-negative diseaseNode-positive diseaseDecrease treatment toxicityNeck cancer patientsPrimary outcome measureConcurrent cetuximabConcurrent chemotherapyLocoregional controlMedian followNodal disease
2023
Post-operative PET/CT improves the detection of early recurrence of squamous cell carcinomas of the oral cavity
Yu Y, Schöder H, Zakeri K, Chen L, Kang J, McBride S, Tsai C, Gelblum D, Boyle J, Cracchiolo J, Cohen M, Singh B, Ganly I, Patel S, Michel L, Dunn L, Sherman E, Pfister D, Wong R, Riaz N, Lee N. Post-operative PET/CT improves the detection of early recurrence of squamous cell carcinomas of the oral cavity. Oral Oncology 2023, 141: 106400. PMID: 37099979, PMCID: PMC10631462, DOI: 10.1016/j.oraloncology.2023.106400.Peer-Reviewed Original ResearchConceptsOral squamous cell carcinomaIntermediate-risk featuresPET/CTHigh-risk featuresPost-operative radiationSquamous cell carcinomaEarly recurrenceRisk featuresSurgical marginsCell carcinomaPET/CT planningAddition of chemotherapyClose surgical marginsDisease-free survivalPositive surgical marginsRecords of patientsPositron emission tomographyTreatment intensificationBaseline characteristicsNode positivityLymphovascular invasionOverall survivalPT3-4Perineural invasionTumor thickness
2022
Treatment Outcomes for Radiation Therapy with Concurrent Carboplatin and Paclitaxel for Locally Advanced Head and Neck Cancer
Han J, Zakeri K, Raab G, Chen L, Yu Y, Kang J, McBride S, Riaz N, Tsai C, Gelblum D, Sherman E, Wong R, Michel L, Lee N. Treatment Outcomes for Radiation Therapy with Concurrent Carboplatin and Paclitaxel for Locally Advanced Head and Neck Cancer. International Journal Of Radiation Oncology • Biology • Physics 2022, 114: e317. DOI: 10.1016/j.ijrobp.2022.07.1381.Peer-Reviewed Original ResearchProgression-free survivalCisplatin-ineligible patientsDefinitive radiation therapyUnknown primary cancerLocoregional controlRadiation therapyDistant controlConcurrent carboplatinWeekly carboplatinAdvanced headOverall survivalHNSCC patientsPrimary cancerNeck squamous cell carcinomaConclusions Radiation therapyConsecutive HNSCC patientsCycles of chemotherapySevere ulcerative colitisUpper gastrointestinal bleedMedian radiation doseSynchronous primary malignanciesKaplan-Meier methodSquamous cell carcinomaMATERIAL/METHODSCumulative incidence functionNasal Cavity and Paranasal Sinus Tumors
Fan M, Yu Y, Kang J, Lee N. Nasal Cavity and Paranasal Sinus Tumors. Practical Guides In Radiation Oncology 2022, 87-98. DOI: 10.1007/978-3-030-99590-4_7.Peer-Reviewed Original ResearchParanasal sinusesNasal cavityTumor typesTarget delineationExperienced multidisciplinary teamSquamous cell carcinomaParanasal sinus tumorsDifferent natural historyCentral nervous systemMedical oncologistsSinus tumorAccurate target delineationCell carcinomaOptimal careNeck surgeonsCystic carcinomaNervous systemDiverse tumor typesMultidisciplinary teamRadiation oncologistsSkull baseNatural historyPatientsCarcinomaOncologists
2021
The effect of short radiation treatment breaks on chemo‐radiotherapy for oropharyngeal cancers
Rybkin A, Kang JJ, Lee A, Kitpanit S, Fan M, Mohamed N, Cartano O, Zakeri K, Gelblum D, Sherman E, Dunn L, Boyle J, Wong R, Chen L, Yu Y, McBride SM, Tsai CJ, Riaz N, Lee NY. The effect of short radiation treatment breaks on chemo‐radiotherapy for oropharyngeal cancers. Head & Neck 2021, 43: 3796-3809. PMID: 34585792, PMCID: PMC9414892, DOI: 10.1002/hed.26879.Peer-Reviewed Original ResearchConceptsRadiation treatment breaksOropharyngeal squamous cell carcinomaOverall treatment timeTreatment breaksClinical outcomesDefinitive concurrent chemoradiotherapySquamous cell carcinomaConcurrent chemoradiotherapyOPSCC patientsOropharyngeal cancerDisease failureCell carcinomaNeck cancerCancer recurrenceConsecutive cohortMultivariate analysisSignificant associationPatientsCancerFurther investigationProlongationDaysOutcomesNumerous studiesChemoradiotherapyTERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence
Yu Y, Fan D, Song X, Zakeri K, Chen L, Kang J, McBride S, Tsai CJ, Dunn L, Sherman E, Katabi N, Dogan S, Cracchiolo J, Cohen M, Boyle JO, Lee M, Valero C, Wang J, Wong R, Morris L, Riaz N, Lee N. TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence. JCO Precision Oncology 2021, 5: 1259-1269. PMID: 34381934, PMCID: PMC8345918, DOI: 10.1200/po.20.00515.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaLocoregional failurePatterns of failureCumulative incidenceCell carcinomaPromoter mutationsHPV-positive oropharyngeal squamous cell carcinomaMemorial Sloan-Kettering Cancer CenterRisk of LRFOropharyngeal squamous cell carcinomaNeck squamous cell carcinomaHPV-negative HNSCCsReverse transcriptase (TERT) promoter mutationsOral cavity cancerNext-generation sequencingTERT promoter mutationsDisease subsiteLocoregional recurrenceOverall cohortOverall survivalProspective cohortCancer CenterHuman papillomavirusLaryngopharyngeal cancerUnique pathogenesisPostoperative PET/CT for detection of early recurrence (ER) after surgery for squamous cell carcinomas (SCC) of the oral cavity (OC).
Yu Y, Schöder H, Kang J, McBride S, Tsai C, Chen L, Zakeri K, Gelblum D, Boyle J, Cracchiolo J, Cohen M, Singh B, Ganly I, Patel S, Michel L, Dunn L, Pfister D, Wong R, Riaz N, Lee N. Postoperative PET/CT for detection of early recurrence (ER) after surgery for squamous cell carcinomas (SCC) of the oral cavity (OC). Journal Of Clinical Oncology 2021, 39: 6060-6060. DOI: 10.1200/jco.2021.39.15_suppl.6060.Peer-Reviewed Original ResearchPostoperative PET/CTIntermediate risk factorsSquamous cell carcinomaHigh-risk factorsPET/CTPT3-4 diseasePositive surgical marginsEarly recurrenceSurgical marginsExtranodal extensionLymphovascular invasionPerineural invasionRisk factorsOral cavityPostoperative radiotherapyOverall survivalPostoperative radiationPET/CT planningDistant metastasis-free survivalImproved disease-free survivalClinicopathologic risk factorsClose surgical marginsDisease-free survivalSalvage therapyDistant recurrence
2019
Platinum‐based regimens versus cetuximab in definitive chemoradiation for human papillomavirus‐unrelated head and neck cancer
Beckham TH, Barney C, Healy E, Wolfe AR, Branstetter A, Yaney A, Riaz N, McBride SM, Tsai CJ, Kang J, Yu Y, Chen L, Sherman E, Dunn L, Pfister DG, Tan J, Rupert R, Bonomi M, Zhang Z, Lobaugh SM, Grecula JC, Mitchell DL, Wobb JL, Miller ED, Blakaj DM, Diavolitsis VM, Lee N, Bhatt AD. Platinum‐based regimens versus cetuximab in definitive chemoradiation for human papillomavirus‐unrelated head and neck cancer. International Journal Of Cancer 2019, 147: 107-115. PMID: 31609479, DOI: 10.1002/ijc.32736.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCetuximabChemoradiotherapyCisplatinFemaleHead and Neck NeoplasmsHumansMaleMiddle AgedNeoplasm StagingPapillomaviridaePapillomavirus InfectionsRandomized Controlled Trials as TopicSquamous Cell Carcinoma of Head and NeckSurvival RateConceptsLocoregional failureOverall survivalDistant metastasisReduced hazardMultivariable analysisKaplan-MeierHuman papillomavirus-unrelated headNeck squamous cell carcinomaPlatinum-based regimensSquamous cell carcinomaSuperior locoregional controlCumulative incidence functionDefinitive chemoradiationDefinitive radiotherapyLocoregional controlAdvanced headClinical characteristicsCumulative incidenceConcurrent cetuximabPropensity matchingYear OSCell carcinomaHuman papillomavirusNeck cancerProportional hazardsTiming of surgery and adjuvant radiation therapy for sinonasal malignancies: Effect of surgical approach
Xiao R, Joshi RR, Husain Q, Cracchiolo JR, Lee N, Tsai J, Yu Y, Chen L, Kang JJ, McBride S, Riaz N, Roman BR, Ganly I, Tabar V, Gray ST, Cohen MA. Timing of surgery and adjuvant radiation therapy for sinonasal malignancies: Effect of surgical approach. Head & Neck 2019, 41: 3551-3563. PMID: 31294897, PMCID: PMC6742559, DOI: 10.1002/hed.25873.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, Squamous CellCombined Modality TherapyDatabases, FactualDisease-Free SurvivalEndoscopyFemaleHumansKaplan-Meier EstimateLinear ModelsMaleMiddle AgedOtorhinolaryngologic Surgical ProceduresParanasal Sinus NeoplasmsPropensity ScoreRadiotherapy, AdjuvantRetrospective StudiesRisk AssessmentSurvival AnalysisTime FactorsConceptsSquamous cell carcinomaRadiation therapyEndoscopic surgeryPropensity score-matched analysisAdjuvant radiation therapyNational Cancer DatabasePostoperative radiation therapyKaplan-Meier methodTiming of surgeryDay of surgeryShorter postoperative timeMultivariable linear regressionOverall survivalPostoperative timeSinonasal malignanciesCell carcinomaSurgical approachNeck cancerCancer DatabaseParanasal sinusesSurvival advantageNasal cavitySurgeryPatientsExtended OSA retrospective analysis of cisplatin dosing strategies when used with radiation on outcomes in head and neck squamous cell carcinoma of the oropharynx.
Tchekmedyian V, Ho A, Dunn L, Fetten J, Pfister D, Lobaugh S, Zhang Z, Kang J, Chen L, Riaz N, McBride S, Yu Y, Tsai C, Lee N, Sherman E. A retrospective analysis of cisplatin dosing strategies when used with radiation on outcomes in head and neck squamous cell carcinoma of the oropharynx. Journal Of Clinical Oncology 2019, 37: 6079-6079. DOI: 10.1200/jco.2019.37.15_suppl.6079.Peer-Reviewed Original ResearchHPV/p16 statusOverall survivalRetrospective analysisTotal doseT stageP16 statusMultivariate Cox proportional hazards modelMultivariate analysisMedian f/uCox proportional hazards regressionCox proportional hazards modelNeck squamous cell carcinomaHPV/p16Start of RTProportional hazards regressionSquamous cell carcinomaSplit-dose administrationProportional hazards modelCI dosingPrimary CRTInduction chemotherapyCRT outcomesDistant failureProspective trialMedian age